Introduction
Bladder cancer is one of the most common urological malignancies and represents a significant challenge in oncological care. Although both incidence and mortality have remained stable in recent years, the treatment of advanced and metastatic forms of the disease continues to face considerable limitations.
In response to these challenges, the UROREG project was established to systematically collect and evaluate clinical data from patients with locally advanced and metastatic urothelial carcinoma. This project brings together experts from the Czech Republic and, in the future, also from other European countries, with the aim of optimizing patient care and supporting the advancement of scientific knowledge in the treatment of this serious disease.
About the Project
UROREG is a multicenter registry focused on monitoring patients with locally advanced and metastatic urothelial carcinoma. The project is based on the systematic collection of data related to the course of disease treatment, outcomes of individual therapeutic approaches, the potential of their combinations, and their use across different lines of therapy.
The project is conducted under the professional auspices of the Czech Society for Oncology of the Czech Medical Association of J. E. Purkyně. It involves oncology centers specialized in providing high-cost and innovative treatments for bladder cancer. The registry will be open to participation by centers from both the Czech Republic and other European Union countries. As such, the project will create a unique platform for sharing clinical data with the potential to foster scientific research and improve clinical practice.
Objectives
Primary Objective:
- To collect epidemiological and clinical data and to monitor the course of treatment in patients diagnosed with bladder cancer.
Secondary Objectives:
- To evaluate the effectiveness of the observed treatment and therapeutic regimens used.
- To monitor the various types of treatment administered, including radiotherapy and surgical procedures.
- To assess patient survival in relation to the monitored clinical factors.
- To evaluate treatment sequence strategies, time to progression, and overall survival.
- To assess the safety of the observed treatment.
Guarantee
Expert Guarantee
The registry operates under the auspices of the Czech Society for Oncology of the Czech Medical Association of J. E. Purkyně.
The registry is supervised by Assoc. Prof. Alexandr Poprach, MD, Ph.D.
Project Management
- Institute of Biostatistics and Analyses, Ltd., a spin-off company of Masaryk University, ensures management and other service activities for this project
- Mgr. Adéla Vojkůvková, Project Manager
- Ing. Petr Brabec, Ph.D., Managing Director